As novel therapies such as APOC3 inhibitors progress from phase 2 studies to larger-scale phase 3 studies of CVD prevention, then patients with AAA could be an important CVD subphenotype in whom treatment should be evaluated. This evidence concerns the gene APOC3 and triple-A syndrome.